Navigation Links
Bioniche Responds to Australian Equine Influenza Outbreak

- Equimune(R) IV product a proven treatment -

BELLEVILLE, ON, Sept. 6 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has increased its supply of Equimune(R)IV to Australia in order to be able to respond to anticipated increased demand as a result of that continent's equine influenza outbreak. The outbreak began in August, and according to one media report, a total of 3,376 horses on 405 properties are now suspected of having the virus.

"Bioniche wants to ensure that sufficient supply of Equimune IV is available to Australian veterinarians," said Jim Phillips, President of Bioniche Animal Health (global). "At the same time, we are ensuring that veterinarians have the information they require about our proprietary immunotherapy product and its efficacy in the treatment of equine influenza."

Equine influenza is a viral respiratory infection that causes flu like symptoms in horses and is from the group of viruses that causes flu in humans. Most horses exposed to the virus will show signs within a period of 1-5 days. Most viruses that are responsible for coughs and colds in horses result in mild symptoms, such as nasal discharge and coughing. Equine Influenza produces more severe symptoms, with horses developing a fever and a dry hacking cough. Horses become ill and are reluctant to eat or drink for several days, but usually recover in 2 to 3 weeks. The virus can be spread easily from horse to horse as a result of droplets and also from nasal discharge and from things like infected brushes and rugs. The disease is very contagious and there can be an almost 100% infection rate in a population that has been previously unexposed to the virus.

Australia and New Zealand are the only countries with significant equine industries that have been previously free from equine influenza. Horses in Australia are not vaccinated. This outbreak of equine influenza is expected to have a major impact on the multibillion-dollar equine stud and racing industries. Quarantine programs have been developed for the safe movement of horses internationally for breeding, racing, and other purposes. Increased international movement of horses for breeding and competition purpose constitutes an important factor in the spread of equine influenza throughout the world.

"Equimune IV has been an excellent tool used in our practice both to treat viral respiratory infections and as a preventative aid used in the face of an outbreak," said Dr. Richard C. Mather II, DVM of the Woodland Run Equine Clinic in Grove City, Ohio. "For best results, we advise that horses not be stressed for 24 hours following treatment with Equimune IV."

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs approximately 195 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop proprietary cancer therapies supported by revenues from marketed products in human and animal health. For more information, please visit

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

SOURCE Bioniche Life Sciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Acute Gastroenteritis Responds To Treatment With Either Gatorade Or Pedialyte
2. Marijuana Abuse Responds to Psychotherapy, Overall Is Hard to Treat
3. Stubborn Ulcerative Colitis Responds to Arthritis Drug
4. Brain Responds Better to Name Brands
5. Australian Scientists Silence Cancer Gene
6. Australian Government To Stockpile Anti-Bird Flu Drug Relenza
7. Australian Company Gets $10 million For Developing Skin Cancer Gel
8. World’s First Triple Transplant Performed by Australian Surgeon
9. Australian Surgeons Successfully Conduct Worlds First Triple Organ Transplant
10. Six Indians Win Australian Studies Fellowships
11. Australian Health funds stand accused
Post Your Comments:
(Date:12/1/2015)... ... , ... It’s official: Tattoo taboo is a thing of the past. One ... (a whopping one in three aged 18 to 25 is inked). As tattoos transition ... ink. In fact, RealSelf , the world’s largest community for learning and sharing ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... technicians must mark the film for accurate interpretation by the radiologist. The marking ... an inventor from Sacramento, Calif., has found a way to alleviate this problem. ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... it has been selected as a finalist in this year’s Fierce Innovation Awards: ... Next IT Healthcare was recognized as a finalist in the category of Digital ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... the Field for Effective Post-Affiliation Integration ,” addresses a main “pain point” for ... deliver the anticipated results, once a deal is signed. This quick-read guidance ...
(Date:12/1/2015)... China (PRWEB) , ... December 01, 2015 , ... Nurotron ... result in its largest order to date. , The order will be from ... systems. Nurotron’s Venus Cochlear Implant System is an effective solution for children and adults ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Sweden , December 1, 2015 ... Cancer Study Group (IBCSG, Bern ) and ... to be part of a state of the art trial, ... --> --> The study, ... treated with anti-hormonal therapy in combination with palbociclib, a cancer ...
(Date:11/30/2015)... BASEL, Switzerland , Dec. 1, 2015 ... through its wholly-owned UK subsidiary Proximagen Ltd., today announced ... novel, oral small molecule inhibitor of Vascular Adhesion Protein ... in the treatment of inflammatory disease. The VAP-1 inhibitor ... --> --> Under the terms ...
(Date:11/30/2015)... Asia,s largest exhibition and conference dedicated to the Medical Device ... 22 nd April 2016. --> --> ... --> -->   --> --> ... population and the government back up, the Medical Device is one of the ... . With the aging population and the government back up, the Medical ...
Breaking Medicine Technology: